India, June 18 -- Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month.
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist, while topiramate is an anticonvulsant medication also approved for migraine prevention.
Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versu...